Adamantane-derived adaptogen
A Soviet-developed adamantane derivative (Ladasten) approved in Russia for asthenia with mixed psychostimulant and anxiolytic effects.
Abstract
Bromantane (Ladasten; ADK-709; N-(2-adamantyl)-N-(p-bromophenyl)amine; CAS 87913-26-6; molecular formula C16H20BrN; molecular weight 306.24) is an adamantane derivative developed in the Soviet Union in the 1980s, originally for military applications (combat fatigue, cold tolerance). The compound is approved in Russia as Ladasten for asthenia and neurasthenia. Pharmacology is distinctive: bromantane combines mild dopaminergic activation (through enhanced dopamine synthesis rather than transporter inhibition or release) with anxiolytic effects through a non-GABAergic mechanism. The combination produces a clinical profile described as “actoprotective” . improving physical and mental performance under stress without the rebound fatigue typical of stimulants or the sedation typical of anxiolytics. Bromantane is on the WADA prohibited list (banned in 1996). Pharmacokinetics: plasma half-life 9 to 12 hours; oral bioavailability good. Russian clinical literature is substantial; English-language randomized trials are limited.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.